ReviewDiscover nano2026
Nanotechnology-based strategies for helminth control: drug delivery, green nanoparticles, mechanisms, and translational barriers.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parasitic helminth infections remain a major global health burden in humans and livestock, with treatment hindered by drug resistance, poor bioavailability, and rapid degradation of conventional anthelmintics. Nanotechnology offers effective alternatives through nanocarrier systems (polymeric, lipid, metallic, and green-synthesized) that enhance drug solubility, stability, targeted delivery, and sustained release, while reducing toxicity. These nanomaterials exert anthelmintic effects through tegumental disruption, oxidative stress induction, metabolic interference, and immune modulation. Several preclinical studies have reported improved efficacy, bioavailability, or dose-sparing potential compared with conventional formulations; however, the available evidence remains heterogeneous. However, clinical translation faces barriers including scale-up, regulatory hurdles, and environmental safety concerns. This review critically evaluates current nanotechnological platforms, identifies key mechanistic pathways, and outlines future research directions within a One Health framework to guide the development of effective and sustainable nanoscale anthelmintic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.